Orchestra BioMed Holdings, Inc.

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed is a biomedical innovation company focused on accelerating high-impact medical technologies to patients through risk-reward sharing partnerships with leading medical device companies. Their partnership-enabled business model emphasizes strategic collaborations for global commercialization of developed products.

Products & Services

BackBeat Cardiac Neuromodulation Therapy™ (AVIM therapy):An investigational bioelectronic treatment for hypertension designed to provide immediate, substantial, and persistent blood pressure reduction while modulating autonomic nervous system responses.

Virtue® Sirolimus AngioInfusion™ Balloon (SAB):An investigational drug/device combination product for artery disease treatment, delivering an extended-release formulation of sirolimus during balloon angioplasty without coatings or permanent implants.

FreeHold Retractors:A product mentioned in the innovations section, though specific details about its purpose or application are not provided in the content.

Specialties

Hypertension Treatment Atherosclerotic Artery Disease Treatment Bioelectronic Therapies Drug/Device Combination Products

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Acquisition Proceeds T: - FT: Acquisition Proceeds	A: 21000000 MR: - FA: up to $21 million FAN: 21000000	D: 2026-01-12 FD: 2026-01-12	-
2	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 111200000 MR: - FA: $111.2 million FAN: 111200000	D: 2025-08-05 FD: 2025-08-05	2 investors
3	RT: Public Offering T: - FT: Public Offering	A: 40000000 MR: - FA: 40 Million FAN: 40000000	D: 2025-08-01 FD: 2025-08-01	2 investors
4	RT: Strategic Investment (Equity and Convertible Debt) T: - FT: Strategic Investment (Equity and Convertible Debt)	A: 70000000 MR: - FA: $70 million FAN: 70000000	D: 2025-07-31 FD: 2025-07-31	2 investors

Acquisition Proceeds Latest

2026-01-12

$21.0M

Public Offering and Private Placement 2025-08-05

$111.2M

Public Offering 2025-08-01

$40.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David P. Hochman

Chairman of the Board of Directors, CEO and Founder

D

Darren R. Sherman

President, COO and Director

A

Andrew Taylor

Chief Financial Officer

Y

Yuval Mika

General Manager and Chief Technology Officer, Bioelectronic Therapies

H

Hans-Peter Stoll

Chief Clinical Officer

B

Bill Little

Executive Vice President, Corporate Development and Strategy

View 24 more team members with Pro

Unlock Full Team Directory

Recent News